Preclinical Development of PEG-TNF

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$808,828.00
Award Year:
2004
Program:
SBIR
Phase:
Phase II
Contract:
2R44CA085023-02
Agency Tracking Number:
CA085023
Solicitation Year:
2004
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2004-2
Small Business Information
PHOENIX PHARMACOLOGICS, INC.
PHOENIX PHARMACOLOGICS, INC., ASTECC FACILITY #A-217, LEXINGTON, KY, 40506
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JOHN Bomalaski
(610) 524-7710
JOHNSBOMALASKI@MSN.COM
Business Contact:
MIKE CLARK
(859) 257-9027
MCLARK@PHOENIXPHARM.ORG
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Unformulated human tumor necrosis factor( (huTNF() has anti-tumor activity in mice, but there is little difference between the effective and lethal doses. Systemic administration of unformulated huTNFalpha has been te

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government